Aethlon Medical (NASDAQ:AEMD) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued on Friday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Aethlon Medical in a report on Monday, March 10th.

Aethlon Medical Stock Performance

Shares of NASDAQ:AEMD opened at $0.40 on Friday. Aethlon Medical has a 52-week low of $0.24 and a 52-week high of $1.79. The business’s 50 day simple moving average is $0.56 and its two-hundred day simple moving average is $0.50. The firm has a market cap of $5.80 million, a P/E ratio of -0.25 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last issued its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. On average, equities analysts forecast that Aethlon Medical will post -0.73 earnings per share for the current fiscal year.

Institutional Trading of Aethlon Medical

Several institutional investors and hedge funds have recently modified their holdings of the stock. Allegiance Financial Group Advisory Services LLC purchased a new position in shares of Aethlon Medical during the fourth quarter valued at approximately $26,000. Renaissance Technologies LLC bought a new position in Aethlon Medical during the 4th quarter valued at $25,000. Boothbay Fund Management LLC purchased a new position in Aethlon Medical during the 4th quarter worth $186,000. Sassicaia Capital Advisers LLC bought a new stake in shares of Aethlon Medical in the 4th quarter worth $31,000. Finally, Virtu Financial LLC bought a new stake in shares of Aethlon Medical in the 4th quarter worth $81,000. 1.99% of the stock is owned by hedge funds and other institutional investors.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.